HEAL Initiative: Non-addictive Analgesic Therapeutics Development [Small Molecules and Biologics] to Treat Pain (UG3/UH3 Clinical Trial Optional)
The summary for the HEAL Initiative: Non-addictive Analgesic Therapeutics Development [Small Molecules and Biologics] to Treat Pain (UG3/UH3 Clinical Trial Optional) grant is detailed below.
This summary states who is eligible for the grant, how much grant money will be awarded, current and past deadlines, Catalog of Federal Domestic Assistance (CFDA) numbers, and a sampling of similar government grants.
Verify the accuracy of the data FederalGrants.com provides by visiting the webpage noted in the Link to Full Announcement section or by contacting the appropriate person listed as the Grant Announcement Contact.
If any section is incomplete, please visit the website for the National Institutes of Health, which is the U.S. government agency offering this grant.
HEAL Initiative: Non-addictive Analgesic Therapeutics Development [Small Molecules and Biologics] to Treat Pain (UG3/UH3 Clinical Trial Optional): Reissue of RFA-NS-20-010: The purpose of this funding opportunity announcement (FOA) is to support preclinical optimization and development of safe, effective, and non-addictive small molecule and biologic therapeutics to treat pain. The goal of the program is to accelerate the optimization and development of promising small molecule and biologic hits/leads towards clinical trials. Applicants must have a promising hit/lead, robust biological rationale for the intended approach, and identified assays for optimization of the agent. The scope of this program includes optimization and early development activities, IND-enabling studies, and assembly of Investigational New Drug (IND) application. This is a milestone-driven phased cooperative agreement program involving participation of NIH program staff in the development of the project plan and monitoring of research progress.
Federal Grant Title: | HEAL Initiative: Non-addictive Analgesic Therapeutics Development [Small Molecules and Biologics] to Treat Pain (UG3/UH3 Clinical Trial Optional) |
Federal Agency Name: | National Institutes of Health (HHS-NIH11) |
Grant Categories: | Education Food and Nutrition Health Income Security and Social Services |
Type of Opportunity: | Discretionary |
Funding Opportunity Number: | RFA-NS-24-019 |
Type of Funding: | Cooperative Agreement |
CFDA Numbers: | 93.121, 93.213, 93.233, 93.273, 93.279, 93.313, 93.395, 93.837, 93.838, 93.839, 93.840, 93.846, 93.847, 93.853, 93.865, 93.866, 93.867 |
CFDA Descriptions: | Information not provided |
Current Application Deadline: | January 7th, 2027 |
Original Application Deadline: | January 7th, 2027 |
Posted Date: | October 31st, 2023 |
Creation Date: | October 31st, 2023 |
Archive Date: | February 12th, 2027 |
Total Program Funding: | |
Maximum Federal Grant Award: | |
Minimum Federal Grant Award: | |
Expected Number of Awards: | |
Cost Sharing or Matching: | No |
Last Updated: | November 2nd, 2023 |
- Applicants Eligible for this Grant
- State governments - County governments - City or township governments - Special district governments - Independent school districts - Public and State controlled institutions of higher education - Native American tribal governments (Federally recognized) - Public housing authorities/Indian housing authorities - Native American tribal organizations (other than Federally recognized tribal governments) - Nonprofits having a 501 (c) (3) status with the IRS, other than institutions of higher education - Nonprofits that do not have a 501 (c) (3) status with the IRS, other than institutions of higher education - Private institutions of higher education - For-profit organizations other than small businesses - Small businesses - Others (see text field entitled "Additional Information on Eligibility" for clarification.)
- Additional Information on Eligibility
- Other Eligible Applicants include the following: Alaska Native and Native Hawaiian Serving Institutions; Asian American Native American Pacific Islander Serving Institutions (AANAPISISs); Eligible Agencies of the Federal Government; Faith-based or Community-based Organizations; Hispanic-serving Institutions; Historically Black Colleges and Universities (HBCUs); Indian/Native American Tribal Governments (Other than Federally Recognized); Non-domestic (non-U.S.) Entities (Foreign Organizations); Regional Organizations; Tribally Controlled Colleges and Universities (TCCUs) ; U.S. Territory or Possession; Non-domestic (non-U.S.) Entities (Foreign Organizations) are not eligible to apply. Non-domestic (non-U.S.) components of U.S. Organizations are not eligible to apply. Foreign components, as defined in the NIH Grants Policy Statement, are allowed.
- Link to Full Grant Announcement
- https://grants.nih.gov/grants/guide/rfa-files/RFA-NS-24-019.html
- Grant Announcement Contact
- NIH Grants Information
[email protected]
See Section VII. Agency Contacts within the full opportunity announcement for all other inquires. - Similar Government Grants
- • Independent Scientist Award (Parent K02 - Independent Clinical Trial Not Allowed)
- • HEAL Initiative-Early-Stage Discovery of New Pain Targets Within the Understudied Druggabl...
- • NIDCR Predoctoral to Postdoctoral Transition Award to Promote a Diverse Dental, Oral and C...
- • Rare Diseases Clinical Research Consortia (RDCRC) for the Rare Diseases Clinical Research ...
- • HEAL Initiative: Studies to Enable Analgesic Discovery (R61/R33 - Clinical Trial Not Allow...
- • Epidemiological and Behavioral Research in Oral Health
- • Metagenomic Analyses of the Oral Microbiome
- • Phase Iii Clinical Trials in Oral Infectious Diseases
- More Grants from the National Institutes of Health
- • ML/AI Tools to Advance Genomic Translational Research (MAGen) - Development Sites (UG3/U...
- • ML/AI Tools to Advance Genomic Translational Research (MAGen) - Coordinating Center (UG3/U...
- • Mentored Career Development Award to Promote Faculty Diversity in Biomedical Research (K01...
- • Mentored Career Development Award to Promote Faculty Diversity in Biomedical Research (K01...
- • Senator Paul D. Wellstone Muscular Dystrophy Specialized Research Centers (MDSRC) (P50 Cli...